UBS analyst Colin Bristow upgraded Sarepta to Buy from Neutral with a price target of $158, up from $100, telling investors that he views it as "highly likely" that accelerated approval is granted for SRP-9001 in Duchenne muscular dystrophy, or DMD, by the PDUFA date of May 29. He believes Sarepta has sufficient data to support the use and he has increased his odds of approval to 85% from 60%, the analyst added.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SRPT:
- Sarepta price target raised to $174 from $150 at Cantor Fitzgerald
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Biotech Alert: Searches spiking for these stocks today
- Catalent had 483s cleared, removing overhang, says Barclays
- Sarepta announces FDA grants priority review for SRP-9001 BLA
